海力特治疗慢性乙型肝炎临床观察  

A CLINICAL OBSERVATION ON HAILITE(HLT) IN TREATING CHRONIC HEPATITIS B

作　　者：潘兆随[1] 李志娟[1] 唐保禄[1] 陈淑慎 李宗欣[1] 代兆举[1] 李梅[1] 王杰刚[1] 郭常同[1] 

机构地区：[1]山东省日照市人民医院,日照276800 [2]山东省日照市石臼医院

出　　处：《中国海洋药物》1996年第1期36-38,共3页Chinese Journal of Marine Drugs

摘　　要：采用海洋药物海力特治疗慢性乙型肝炎25例,并与猪苓多糖加乙肝疫苗治疗作为对照。结果表明,海力特治疗慢性乙型肝炎总有效率为88.0％,ALT复常率86.96％,HBeAg转阴率40.91％,与猪苓多糖加乙肝疫苗的疗效无显著性差异(P>0.05)。Twenty five patients with chronic hepatitis B were treated with a new marine drug HAILITE (HLT) ,and compared with a control group treated with Zhuling Duotang. The results showed that the total effective rate of the treating group (HLT) was 88. 0 per cents.the recovery rate of ALT was 86. 96 percents.and the rate of HBeAg returning negative. 40. 91 per cents. There was no significant difference between the two groups ( P >0. 05).

关 键 词：海力特 乙型肝炎 药物疗法 

分 类 号：R512.620.5[医药卫生—内科学]